<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175431</url>
  </required_header>
  <id_info>
    <org_study_id>RG1004972</org_study_id>
    <secondary_id>NCI-2019-07437</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>10349</secondary_id>
    <nct_id>NCT04175431</nct_id>
  </id_info>
  <brief_title>Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study</brief_title>
  <official_title>Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blue Earth Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well fluciclovine positron emission tomography (PET)/computed
      tomography (CT) improves long-term outcomes by facilitating early identification of
      metastatic prostate cancer amenable to both systemic and site-directed definitive therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are assigned to 1 of 3 groups.

      GROUP I (observation with fluciclovine PET/CT): Patients who do not have any abnormalities
      outside the prostatic fossa by fluciclovine PET/CT imaging undergo prostate-specific antigen
      (PSA) rechecks every 3 months once PSA is &gt; 2 ng/ml. If still no abnormalities are found,
      patients continue to undergo PSA rechecks every 3 months once PSA is &gt; 5 ng/ml. Patients are
      off study once PSA reaches 10 ng/ml.

      GROUP II (ADT/abiraterone/prednisone +/- surgery +/- RT): Patients who have =&lt; 3 regions of
      metastatic disease outside the prostatic fossa may undergo lymphadenectomy and/or radiation
      therapy, depending on the location of metastases. Patients with surgically treatable disease
      receive androgen deprivation therapy (ADT) comprising any luteinizing hormone-releasing
      hormone (LHRH) agent, abiraterone acetate 1000 mg orally (PO) once daily (QD), and prednisone
      PO QD 6 weeks after surgery. Patients with radiation treatable disease receive 2 cycles of
      ADT, abiraterone acetate, and prednisone followed by radiation therapy. Treatment repeats
      every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.

      GROUP III (ADT/abiraterone/prednisone): Patients who have &gt; 3 regions of metastatic disease
      receive ADT, abiraterone acetate, and prednisone as in Group II.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable PSA (&lt; 0.2 ng/mL) rate</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total testosterone</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to reinitiation of antiandrogen therapy (ADT)</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormalities within the prostatic fossa with PSA &lt; 10 ng/mL</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without abnormalities with PSA &lt; 10 ng/mL</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with PSA &lt; 10 mg/mL and &gt; 3 regions of metastatic prostate cancer on fluciclovine PET/CT</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>PSA Level Greater Than or Equal to 0.5</condition>
  <condition>PSA Level Less Than Ten</condition>
  <arm_group>
    <arm_group_label>Group I (observation with fluciclovine PET/CT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who do not have any abnormalities outside the prostatic fossa by fluciclovine PET/CT imaging undergo PSA rechecks every 3 months once PSA is &gt; 2 ng/ml. If still no abnormalities are found, patients continue to undergo PSA rechecks every 3 months once PSA is &gt; 5 ng/ml. Patients are off study once PSA reaches 10 ng/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have =&lt; 3 regions of metastatic disease outside the prostatic fossa may undergo lymphadenectomy and/or radiation therapy, depending on the location of metastases. Patients with surgically treatable disease receive ADT comprising any LHRH agent, abiraterone acetate 1000 mg PO QD, and prednisone PO QD 6 weeks after surgery. Patients with radiation treatable disease receive 2 cycles of ADT, abiraterone acetate, and prednisone followed by radiation therapy. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (ADT/abiraterone/prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have &gt; 3 regions of metastatic disease receive ADT, abiraterone acetate, and prednisone as in Group II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fluciclovine-PET/CT scan</intervention_name>
    <description>Undergo fluciclovine PET/CT</description>
    <arm_group_label>Group I (observation with fluciclovine PET/CT)</arm_group_label>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <arm_group_label>Group III (ADT/abiraterone/prednisone)</arm_group_label>
    <other_name>Medical Imaging</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography</other_name>
    <other_name>Computed Tomography</other_name>
    <other_name>CAT Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphadenectomy</intervention_name>
    <description>Undergo lymphadenectomy</description>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <other_name>Lymph Node Dissection</other_name>
    <other_name>lymph node excision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <arm_group_label>Group III (ADT/abiraterone/prednisone)</arm_group_label>
    <other_name>154229-18-2</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <arm_group_label>Group III (ADT/abiraterone/prednisone)</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Rayos</other_name>
    <other_name>Sterapred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LHRH agent</intervention_name>
    <description>ADT with LHRH agent</description>
    <arm_group_label>Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)</arm_group_label>
    <arm_group_label>Group III (ADT/abiraterone/prednisone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have histologically or cytologically documented evidence of prostate
             adenocarcinoma

          -  Patient must previously have undergone radical prostatectomy

          -  Patient must previously have undergone either adjuvant or salvage radiation therapy to
             the prostatic fossa +/- whole pelvis

          -  PSA doubling time must be calculated utilizing all PSA measurements from most recent
             biochemically-recurred (BCR). PSA doubling time must be &gt; 3 months and &lt; 18 months.
             The Memorial Sloan Kettering PSA doubling time calculator should be used

          -  Patient must have no previous evidence of radiographically detectable metastatic
             prostate cancer by conventional CT and bone scan imaging

          -  Patient must have total testosterone level &gt; 120 ng/dL demonstrated within 28 days of
             enrollment

          -  Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
             1

          -  Absolute neutrophil count (ANC) &gt;= 1.0 X 10^9/L

          -  Platelet count &gt;= 100 X 10^9/L

          -  Hemoglobin &gt;= 9 g/dL

          -  Potassium &gt;= 3.5

          -  Serum bilirubin =&lt; 1.5 X upper limit of normal (ULN) or =&lt; 3 X ULN for patients with
             documented Gilbert's syndrome

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 3 X ULN

          -  Creatinine clearance (Cr Cl) &gt;= 30 mL/min as estimated by the Cockcroft-Gault criteria
             or as determined by 24 hour Cr Cl measurement

          -  Patient must be able to understand and authorize informed consent

        Exclusion Criteria:

          -  Chronic active hepatitis B or C

          -  History of a second, non-prostate malignancy that required systemic therapy in the
             last 2 years except cancer in situ of bladder and non-melanomatous cancers of the skin

          -  Patient with a serious underlying medical condition that would otherwise impair the
             patient's ability to undergo fluciclovine PET/CT imaging or receive subsequent
             treatment

          -  Any condition that would alter the patient's mental status, prohibiting understanding
             and/or authorization of informed consent

          -  Expected lifespan of less than 12 weeks

          -  Inability to lay still for imaging

          -  Weight &gt; 300 lbs. (due to equipment specifications)

          -  Any other underlying medical condition that, in the opinion of the investigator, would
             impair the ability of the patient to receive or tolerate the planned treatment and/or
             follow up
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Kang</last_name>
    <phone>206-606-1097</phone>
    <email>rkang123@seattlecca.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kang</last_name>
    </contact>
    <investigator>
      <last_name>Evan Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

